Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Prostatic Neoplasm
Interventions: Xofigo (Radium 223 dichloride,BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Prostate Neoplasms
Interventions: PS-341 (bortezomib); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Concussion, Mild Traumatic Brain Injury, Motor Disorders, Cognitive Impairment
Interventions: tDCS in Youth with mild traumatic brain injury; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 15 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Brain Cancer
Interventions: PET scan, C-Choline; Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Jansen's Metaphyseal Chondrodysplasia
Interventions: PTH-IA; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 3 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Talimogene Laherparepvec, Radiation, Cisplatin; Biological · Radiation · Drug
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Canton, Ohio + 2 more

Conditions: Smoking Cessation
Interventions: Intervention, Enhanced Traditional Care control; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Cancer
Interventions: PTC299, Docetaxel; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Low Back Pain, Back Pain, Pain, Chronic Low-back Pain
Interventions: Telehealth Mindfulness Program; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
Interventions: Pancrelipase, Placebo Oral Capsule; Drug
Lead sponsor: Massimo Raimondo, M.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: PTSD, Opioid-use Disorder, Substance Use Disorders
Interventions: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE); Behavioral
Lead sponsor: Christal L Badour; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Schizophrenia
Interventions: Placebo, RO5545965; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Garden Grove, California • Glendale, California • St Louis, Missouri

Conditions: Metabolic Syndrome
Interventions: PP-MI Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Revere, Massachusetts

Conditions: Breast Cancer, Lymphoma
Interventions: PARASYM neuromodulation device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Conditions: Cancer
Interventions: EXCAP, MAAT, ECO; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer
Interventions: Pulmonary Rehab; Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Midazolam, Caffeine, Bupropion; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Vasomotor Symptoms
Interventions: Acupuncture; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Interventions: Cisplatin, Pembrolizumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Anxiety
Interventions: FW-200; Device
Lead sponsor: Fisher Wallace Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • Seattle, Washington

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: SYNB8802, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: AZD6765, Placebo to AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Behavioral Activation Therapy App, Telehealth Delivered Behavioral Activation; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Treatment Patterns in Metastatic Prostate Cancer

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

Safety and Efficacy of PTH-IA

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Patient Navigation and Financial Incentives to Promote Smoking Cessation

PTC299 for Treatment of Advanced Cancer

Feasibility of Telehealth Mindfulness for Back Pain in the Emergency Department

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Trauma and Trauma-Focused Therapy in the University of Kentucky SMART Clinic

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Developing a Positive Psychology Intervention to Promote Health Behaviors in Metabolic Syndrome: RCT

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

Accelerated Pulmonary Rehabilitation in the Preoperative Period

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Acupuncture in Menopause

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

A Study Comparing Immediate Treatment to Deferred Treatment With the Fisher Wallace (FW) Stimulator FW-200 Device for the Treatment of Self-reported Anxiety in First Responders

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

This is a Study to Determine the Antidepressant Effects of AZD6765

Digitally Enhanced Stepped-Care for Depression in Primary Care